For the first time, scientists at University of Cambridge have been able to map in detail the pathway that generates "aberrant" forms of proteins which are at the root of conditions such as Alzheimer's.
They believe the breakthrough established by Professor Christopher Dobson opens up possibilities for a new generation of targeted drugs, as scientists say they have uncovered the earliest stages of the development of Alzheimer's that drugs could possibly target.
Protein molecules are made in cellular 'assembly lines' that join together chemical building blocks called amino acids in an order encoded in our DNA. New proteins emerge as long, thin chains that normally need to be folded into compact and intricate structures to carry out their biological function.
Under some conditions, however, proteins can 'misfold' and snag surrounding normal proteins, which then tangle and stick together in clumps which build to masses, frequently millions, of malfunctioning molecules that shape themselves into unwieldy protein tendrils.
More From This Section
Amyloid fibrils can form the foundations of huge protein deposits - or plaques - long-seen in the brains of Alzheimer's sufferers, and once believed to be the cause of the disease, before the discovery of 'toxic oligomers'.
The new work, in large part carried out by researcher Samuel Cohen, shows that once a small but critical level of malfunctioning protein 'clumps' have formed, a runaway chain reaction is triggered that multiplies exponentially the number of these protein composites, activating new focal points through 'nucleation'.
Small and highly diffusible, these are the 'toxic oligomers' that careen dangerously around the brain cells, killing neurons and ultimately causing loss of memory and other symptoms of dementia.
The study was published in the Proceedings of the National Academy of Sciences.